GPCR.O Surges Past 5-Day SMA Amid Positive Sentiment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 22 2025
0mins
Should l Buy GPCR?
Source: Coinmarketcap
Shares of GPCR.O experienced a notable increase today, crossing above the 5-day simple moving average (SMA) for the first time in several weeks. This technical breakout suggests a potential shift in momentum, as traders often view such movements as a bullish signal. The surge in price can be attributed to recent positive sentiment surrounding the company's upcoming product launch, which has garnered increased investor interest. Analysts are closely monitoring this development, as sustained trading above the 5-day SMA could indicate further upward potential in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GPCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.150
Low
65.00
Averages
106.50
High
140.00
Current: 39.150
Low
65.00
Averages
106.50
High
140.00
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ACT Capital Management Fully Exits Structure Therapeutics Stake
- Complete Exit: ACT Capital Management sold all 38,500 shares of Structure Therapeutics in Q1 2026, with an estimated trade value of $2.63 million, indicating a full exit that reflects a cautious stance amid biotech market volatility.
- Net Position Change: The transaction resulted in a $2.68 million decrease in ACT's net position, suggesting that after a significant price increase, management opted to lock in profits at a high point to mitigate potential market risks.
- Strong Company Performance: As of May 7, 2026, Structure Therapeutics shares were priced at $39.15, up 47% over the past year, outperforming the S&P 500 by 17 percentage points, highlighting its robust growth potential in chronic disease treatment.
- Strong Financial Position: Structure ended the quarter with approximately $1.5 billion in cash and short-term investments, which is expected to fund operations through the end of 2028, enhancing its competitive edge in future product development and commercialization.
See More
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
- Strong Buy Rating: Raymond James reiterated a 'Strong Buy' rating on Viking Therapeutics (VKTX) with a $118 price target, implying a substantial 258% upside, reflecting analysts' strong confidence in the company's future performance.
- Financial Expectations: Consensus estimates anticipate VKTX will report a GAAP loss per share of $1.03, widening from last year's $0.4 loss, with projected EBITDA losses nearing $129.5 million, indicating ongoing financial pressures as the company remains in the clinical stage.
- Clinical Trial Progress: Investor focus remains on the ongoing Phase 3 Vanquish obesity treatment program, with enrollment for the second phase completed in March and results from a maintenance-dose study expected in Q3, highlighting strong demand for new treatment options.
- Intensifying Market Competition: As emerging biotech firms and large pharma companies expand their obesity drug pipelines, competition is intensifying, with Viking facing challenges from companies like Structure Therapeutics and Altimmune, while Eli Lilly's new drug Foundayo shows slower initial prescription data.
See More
Viking Therapeutics Q1 Earnings Preview Highlights Losses and Market Potential
- Earnings Loss Forecast: Koyfin estimates a Q1 GAAP loss per share of $1.03 for Viking Therapeutics, widening from a $0.4 loss a year earlier, indicating ongoing losses during the clinical development phase with zero expected revenue as commercial sales have not yet commenced.
- Clinical Trial Progress: Investor focus remains on the Vanquish program, which completed enrollment for Vanquish-2 in March, evaluating a 78-week weight reduction treatment, reflecting strong demand for additional obesity treatment options as noted by CEO Brian Lian regarding rapid enrollment.
- Intensifying Market Competition: The obesity drug market is becoming increasingly competitive, with Viking's main rival Structure Therapeutics reporting over 16% weight loss from its oral GLP-1 candidate over ten months, while Amazon has launched an integrated GLP-1 treatment platform, intensifying competition in the sector.
- Analyst Optimism: Despite the anticipated losses, Koyfin projects a 174% upside for VKTX stock with a 12-month price target of $92.72, as coverage from 19 analysts mostly reflects a 'Strong Buy' consensus, indicating market confidence in its obesity drug development.
See More
Structure Therapeutics Appoints New COO
- Executive Appointment: Structure Therapeutics has appointed Matthew Lang as Chief Operating Officer, bringing over 15 years of executive leadership experience in global biopharmaceutical organizations, which is expected to positively impact the company's strategic development.
- Legal and Compliance Expertise: While serving as Chief Legal Officer at Metsera, Lang successfully guided the company through an acquisition valued at up to $10 billion, showcasing his deep expertise in legal and compliance matters that will aid Structure Therapeutics in risk management.
- Business Development Background: Prior to joining Structure Therapeutics, Lang held the position of Chief Business and Legal Officer at Lyell Immunopharma, and his extensive business development experience will support the company in expanding its operations in a competitive market.
- Market Reaction: Following the announcement of Lang's appointment, Structure Therapeutics' stock rose 1.76% in after-hours trading to $54.27, reflecting market optimism regarding the new COO's potential contributions.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
SPDR S&P China ETF Analysts See 34.69% Upside
- ETF Target Price Analysis: The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19 per unit, with a current trading price of $92.21, indicating a 34.69% upside potential that reflects market optimism about the ETF's future performance.
- Stock Potential Unveiled: Legend Biotech Corp (LEGN) trades at $19.14, while analysts set a target price of $60.63, suggesting a remarkable 216.78% upside, highlighting the company's strong growth potential in the biotech sector.
- Structure Therapeutics Outlook: Structure Therapeutics Inc (GPCR) is priced at $53.48, with an analyst target of $109.00, indicating a potential increase of 103.81%, showcasing market expectations for its innovative drug development.
- Market Confidence in VNET: VNET Group Inc (VNET) currently trades at $8.19, with an analyst target price of $16.34, reflecting a 99.55% upside, which indicates investor confidence in its future performance.
See More
ACT Capital Management Fully Exits Structure Therapeutics Stake
- Complete Exit: ACT Capital Management sold all 38,500 shares of Structure Therapeutics in Q1 2026, with an estimated trade value of $2.63 million, indicating a full exit that reflects a cautious stance amid biotech market volatility.
- Net Position Change: The transaction resulted in a $2.68 million decrease in ACT's net position, suggesting that after a significant price increase, management opted to lock in profits at a high point to mitigate potential market risks.
- Strong Company Performance: As of May 7, 2026, Structure Therapeutics shares were priced at $39.15, up 47% over the past year, outperforming the S&P 500 by 17 percentage points, highlighting its robust growth potential in chronic disease treatment.
- Strong Financial Position: Structure ended the quarter with approximately $1.5 billion in cash and short-term investments, which is expected to fund operations through the end of 2028, enhancing its competitive edge in future product development and commercialization.
See More
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
- Strong Buy Rating: Raymond James reiterated a 'Strong Buy' rating on Viking Therapeutics (VKTX) with a $118 price target, implying a substantial 258% upside, reflecting analysts' strong confidence in the company's future performance.
- Financial Expectations: Consensus estimates anticipate VKTX will report a GAAP loss per share of $1.03, widening from last year's $0.4 loss, with projected EBITDA losses nearing $129.5 million, indicating ongoing financial pressures as the company remains in the clinical stage.
- Clinical Trial Progress: Investor focus remains on the ongoing Phase 3 Vanquish obesity treatment program, with enrollment for the second phase completed in March and results from a maintenance-dose study expected in Q3, highlighting strong demand for new treatment options.
- Intensifying Market Competition: As emerging biotech firms and large pharma companies expand their obesity drug pipelines, competition is intensifying, with Viking facing challenges from companies like Structure Therapeutics and Altimmune, while Eli Lilly's new drug Foundayo shows slower initial prescription data.
See More
Viking Therapeutics Q1 Earnings Preview Highlights Losses and Market Potential
- Earnings Loss Forecast: Koyfin estimates a Q1 GAAP loss per share of $1.03 for Viking Therapeutics, widening from a $0.4 loss a year earlier, indicating ongoing losses during the clinical development phase with zero expected revenue as commercial sales have not yet commenced.
- Clinical Trial Progress: Investor focus remains on the Vanquish program, which completed enrollment for Vanquish-2 in March, evaluating a 78-week weight reduction treatment, reflecting strong demand for additional obesity treatment options as noted by CEO Brian Lian regarding rapid enrollment.
- Intensifying Market Competition: The obesity drug market is becoming increasingly competitive, with Viking's main rival Structure Therapeutics reporting over 16% weight loss from its oral GLP-1 candidate over ten months, while Amazon has launched an integrated GLP-1 treatment platform, intensifying competition in the sector.
- Analyst Optimism: Despite the anticipated losses, Koyfin projects a 174% upside for VKTX stock with a 12-month price target of $92.72, as coverage from 19 analysts mostly reflects a 'Strong Buy' consensus, indicating market confidence in its obesity drug development.
See More
Structure Therapeutics Appoints New COO
- Executive Appointment: Structure Therapeutics has appointed Matthew Lang as Chief Operating Officer, bringing over 15 years of executive leadership experience in global biopharmaceutical organizations, which is expected to positively impact the company's strategic development.
- Legal and Compliance Expertise: While serving as Chief Legal Officer at Metsera, Lang successfully guided the company through an acquisition valued at up to $10 billion, showcasing his deep expertise in legal and compliance matters that will aid Structure Therapeutics in risk management.
- Business Development Background: Prior to joining Structure Therapeutics, Lang held the position of Chief Business and Legal Officer at Lyell Immunopharma, and his extensive business development experience will support the company in expanding its operations in a competitive market.
- Market Reaction: Following the announcement of Lang's appointment, Structure Therapeutics' stock rose 1.76% in after-hours trading to $54.27, reflecting market optimism regarding the new COO's potential contributions.
See More
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Weight-loss Drugs in Focus: The spotlight is on weight-loss drugs, particularly GLP-1 medications like Wegovy and Zepbound, as they gain popularity.
Market Competition: Eli Lilly and Novo Nordisk are key players in the emerging "diabesity" market, indicating a competitive landscape ahead.
See More
SPDR S&P China ETF Analysts See 34.69% Upside
- ETF Target Price Analysis: The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19 per unit, with a current trading price of $92.21, indicating a 34.69% upside potential that reflects market optimism about the ETF's future performance.
- Stock Potential Unveiled: Legend Biotech Corp (LEGN) trades at $19.14, while analysts set a target price of $60.63, suggesting a remarkable 216.78% upside, highlighting the company's strong growth potential in the biotech sector.
- Structure Therapeutics Outlook: Structure Therapeutics Inc (GPCR) is priced at $53.48, with an analyst target of $109.00, indicating a potential increase of 103.81%, showcasing market expectations for its innovative drug development.
- Market Confidence in VNET: VNET Group Inc (VNET) currently trades at $8.19, with an analyst target price of $16.34, reflecting a 99.55% upside, which indicates investor confidence in its future performance.
See More
